8:25 am Chair’s Opening Remarks
Harnessing Robust Models & Holistic Approaches to Drug Discovery to Better Recapitulate Disease Pathogenesis & Multiple Cardiometabolic Pathologies
8:30 am Holistic Approaches to Cardiometabolic Disease: Common Disease Pathology, Comorbidities & Combination Therapies
Synopsis
- Unlocking next-generation incretin-based therapies as disease-modifying therapies
- Human-centric approaches to drug development: how do we approach the holistic patient view in cardiometabolic disease from a pre-clinical perspectives in the future?
- Two sides of the same coin: navigating holistic approaches to metabolic syndrome to redefine T2D treatment
8:50 am From a Simple Diet-Induced Obese Mouse to Animal Models With Multiple Comorbidities: Moving to Holistic Approaches in Preclinical Drug Efficacy Studies
Synopsis
- Utility and limit of classical obese and diabetic preclinical models
- Why do we need animal models with multiple comorbidities to differentiate novel drugs?
- How multiple comorbidities models help demonstrating therapies potential for patients: examining concrete examples
9:00 am Demonstrating Transformative Weight Loss in in vivo Mice Models Leveraging a Unique Nanoparticle Delivery System
Synopsis
- Combining nanoparticles with a thyroid hormone agonist to reduce weight loss to baseline
- Assessing preclinical results in an obesity model and considering translation to the clinic
- Novel findings from a well-known mechanistic target
9:30 am Panel Discussion: Interrogating in vivo & in vitro Preclinical Models to Understand Pathophysiology & Screen Targets
Synopsis
- Debating the best model: recapitulating complex biology and comorbidities to test therapeutic efficacy
- Tailoring disease models with patient-specific characteristics to execute precision medicine
- From research to therapeutic application: bridging the translational gap
10:00 am Morning Break & Networking
Traversing Robust Outcome Trials & Commercial Strategy to Optimize the Pathway to Market
11:00 am Navigating Clinical Approval in Obesity: From Weight Loss to Life-Changing
Synopsis
- Delineating FDA and EMA requirements in obesity and the pathway to drug approval
- What can we learn from the successful development of Semaglutide and Tirzepatide?
- What is the next step in demonstrating meaningful and long-acting weight loss?
11:30 am Leveraging T2D as a Development Strategy to Forge a Path in Metabolic Indications
Synopsis
- Investigating the clinical path, regulatory, and market access in type 2 diabetes to indicate a more defined pathway into metabolic diseases
- From diabetes to NASH: how can type 2 diabetes represent the first steps?
- Assessing successes and setbacks in clinical strategy and development
12:00 pm Lunch & Networking
Unravelling Novel Opportunities for Drug-Based Management of Obesity & Type 2 Diabetes
1:00 pm Surgery in a Pill™: Harnessing Beneficial Effects of Bariatric Surgery with a Luminal-Targeted Oral Therapy
Synopsis
- Replicating the metabolic effect of bariatric surgery with a short-acting oral drug
- Procedure evolution in the context of 1% of eligible individuals undergoing surgery
- Assessing STAMPEDE results showing remission of T2DM in 30% of patients at five years and 90% able to discontinue insulin
1:30 pm Spotlighting Gut-Mediated Mechanisms of Action to Reimagine Disease-Modifying Targets
Synopsis
- Elucidating the role of gut microbiota in beta cell dysfunction and insulin resistance
- Unlocking gut signalling as disease-modifying therapies and unravelling gut targets based on the learnings from bariatric surgery
- Pioneering a new generation of gut-targeted polymer therapies to improve blood glucose
2:00 pm Afternoon Break & Networking
2:30 pm Leveraging Insulin Sensitizers to Correct the Metabolic Dysfunction Associated with Obesity
Synopsis
- Metabolic reprogramming through a new mitochondrial target for TZD insulin sensitizers facilitated develop of new insulin sensitizers
- New agents lack tolerability issues of direct transcriptional activators and can fully engage insulin sensitizing pharmacology through the newly identified mitochondrial target
- Metabolic reprogramming occurs in multiple cell types to produce a pleiotropic pharmacology, which importantly includes improved response to viral infections
3:00 pm Disease-Modifying Pancreatic Gene Therapies for Type 2 Diabetes & Metabolic Disease
Synopsis
- From chronic disease management to curative therapies in metabolic disease
- Local pancreatic delivery as the key enabler
- Disease-modifying islet-specific gene therapy in type 2 diabetes